View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 26, 2021

AstraZeneca reports positive data for combo therapy to treat BTC

The Imfinzi and chemotherapy combination therapy has showed improvement in patients’ OC.

AstraZeneca has announced positive high-level data from a Phase III trial, which showed that the combination of Imfinzi (durvalumab) and chemotherapy significantly improved overall survival (OS) as a first-line therapy for advanced biliary tract cancer (BTC) patients.

The randomised, double-blind, placebo-controlled, multicentre, global TOPAZ-1 trial enrolled 685 subjects with unresectable advanced or metastatic BTC, including intrahepatic and extrahepatic cholangiocarcinoma; and gallbladder cancer, excluding ampullary carcinoma.

It is being conducted in more than 145 sites in 17 countries such as the US, South America and Europe, as well as many Asian countries, including Japan, China, Thailand, Taiwan and South Korea.

The Independent Data Monitoring Committee has concluded that the trial met the primary endpoint of OS, at a predefined interim analysis.

An improvement in patients’ OC was found when treated with Imfinzi plus chemotherapy combination compared to the treatment with chemotherapy alone.

The combination therapy also met the key secondary endpoints that include improvement in patients’ progression-free survival (PFS), as well as overall response rate.

AstraZeneca Oncology R&D executive vice-president Susan Galbraith said: “We are delighted TOPAZ-1 has been unblinded early due to clear evidence of efficacy for Imfinzi plus chemotherapy, which has also demonstrated a strong safety profile.

“We have now delivered two positive gastrointestinal cancer trials in a row for Imfinzi, following the HIMALAYA trial in liver cancer.

“We believe the significant survival benefit demonstrated marks a new era of immunotherapy treatment in this devastating disease, and it advances our commitment to improving long-term survival for patients across these cancers where treatment options are limited.”

A human monoclonal antibody, Imfinzi attaches to and hinders the interaction of PD-L1 with PD-1 and CD80 proteins. It received Orphan Drug Designation in the US to treat BTC, in December last year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena